Time-Resolved Profiling Reveals ATF3 as a Novel Mediator of Endocrine Resistance in Breast Cancer

Time-Resolved Profiling Reveals ATF3 as a Novel Mediator of Endocrine Resistance in Breast Cancer

Breast cancer is one of the leading causes of death for women worldwide. Patients whose tumors express Estrogen Receptor α account for around 70% of cases and are mostly treated with targeted endocrine therapy. However, depending on the degree of severity of the disease at diagnosis, 10 to 40% of th...

Full description

Bibliographic Details
Main Authors: Simone Borgoni, Emre Sofyalı, Maryam Soleimani, Heike Wilhelm, Karin Müller-Decker, Rainer Will, Ashish Noronha, Lukas Beumers, Pernette J. Verschure, Yosef Yarden, Luca Magnani, Antoine H.C. van Kampen, Perry D. Moerland, Stefan Wiemann
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Cancers
Subjects:
breast cancer
endocrine therapy
drug-resistance
ATF3
RPPA
Online Access:https://www.mdpi.com/2072-6694/12/10/2918

Internet

https://www.mdpi.com/2072-6694/12/10/2918

Similar Items